Pfizer Inc. (NYSE:PFE) Receives $28.13 Average PT from Brokerages

Shares of Pfizer Inc. (NYSE:PFE) have received a consensus recommendation of “Hold” from the eighteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $28.2353.

Several analysts have commented on the stock. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Finally, UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st.

Pfizer Stock Performance

NYSE:PFE opened at $24.68 on Thursday. The stock has a 50-day moving average price of $24.77 and a 200 day moving average price of $24.28. The stock has a market capitalization of $140.29 billion, a P/E ratio of 13.13, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer has a 12-month low of $20.92 and a 12-month high of $28.64. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s payout ratio is 91.49%.

Institutional Investors Weigh In On Pfizer

Several large investors have recently added to or reduced their stakes in the stock. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC increased its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the first quarter valued at $28,000. North Capital Inc. bought a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Finally, Grey Fox Wealth Advisors LLC purchased a new position in shares of Pfizer during the 3rd quarter worth about $29,000. 68.36% of the stock is owned by institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.